
Invus
Description
Invus is a private equity and venture capital firm established in 1985, headquartered in New York City. The firm is renowned for its highly flexible, long-term investment approach, which eschews formulaic strategies in favor of deeply understanding and supporting unique businesses. Invus operates with a sector-agnostic mandate, though it has built a particularly strong track record in consumer products, healthcare, technology, and food and beverage industries. Their philosophy centers on partnering with exceptional management teams to build enduring companies, often providing patient capital over extended periods.
Invus typically invests across various stages, from early-stage venture capital to significant growth equity and even buyouts. They are known for their willingness to take both minority and control stakes, adapting their investment structure to best suit the needs of the company. The firm emphasizes providing strategic guidance and operational support, leveraging its extensive network and experience to help portfolio companies scale and achieve their full potential. This hands-on, yet non-prescriptive, involvement is a hallmark of their partnership model.
The firm manages over $10 billion in capital, enabling them to make substantial commitments to their portfolio companies. Their investment sizes can vary widely, reflecting their flexible approach, but typical first checks for growth equity opportunities often range from tens of millions to hundreds of millions of dollars. Invus has built an extensive portfolio comprising over 100 investments, demonstrating their broad reach and consistent activity in the private markets. Their enduring presence and substantial capital base position them as a significant and patient partner for companies seeking long-term growth.
Investor Profile
Invus has backed more than 253 startups, with 22 new investments in the last 12 months alone. The firm has led 47 rounds, about 19% of its total and boasts 70 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series B, Series C, Post Ipo Equity rounds (top funding stages).
- Majority of deals are located in United States, France, Switzerland.
- Strong thematic focus on Biotechnology, Health Care, Therapeutics.
- Led 3 rounds in the past year.
- Typical check size: $20M – $250M.
Stage Focus
- Series B (24%)
- Series C (17%)
- Post Ipo Equity (17%)
- Series A (16%)
- Series Unknown (13%)
- Series D (6%)
- Series E (2%)
- Private Equity (2%)
- Seed (1%)
- Convertible Note (1%)
Country Focus
- United States (74%)
- France (7%)
- Switzerland (3%)
- United Kingdom (2%)
- China (2%)
- Sweden (2%)
- Finland (2%)
- Ireland (1%)
- Canada (1%)
- Jordan (1%)
Industry Focus
- Biotechnology
- Health Care
- Therapeutics
- Medical
- Life Science
- Pharmaceutical
- Biopharma
- Software
- Genetics
- Information Technology
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.